Chunguang Liang1, Elena Bencurova1, Eric Psota2, Priya Neurgaonkar1, Martina Prelog2, Carsten Scheller3, Thomas Dandekar1. 1. Department of Bioinformatics, Biocenter, Am Hubland, University of Würzburg, 97074 Würzburg, Germany. 2. Department of Pediatrics, Rheumatology and Special Immunology, University Hospital Würzburg, Pediatric Rheumatology/Special Immunology, Josef-Schneider-Str. 2, 97080 Würzburg, Germany. 3. Institute of Virology and Immunobiology, University of Würzburg, Versbacher Str. 7, 97078 Würzburg, Germany.
Abstract
We observed substantial differences in predicted Major Histocompatibility Complex II (MHCII) epitope presentation of SARS-CoV-2 proteins for different populations but only minor differences in predicted MHCI epitope presentation. A comparison of this predicted epitope MHC-coverage revealed for the early phase of infection spread (till day 15 after reaching 128 observed infection cases) highly significant negative correlations with the case fatality rate. Specifically, this was observed in different populations for MHC class II presentation of the viral spike protein (p-value: 0.0733 for linear regression), the envelope protein (p-value: 0.023), and the membrane protein (p-value: 0.00053), indicating that the high case fatality rates of COVID-19 observed in some countries seem to be related with poor MHC class II presentation and hence weak adaptive immune response against these viral envelope proteins. Our results highlight the general importance of the SARS-CoV-2 structural proteins in immunological control in early infection spread looking at a global census in various countries and taking case fatality rate into account. Other factors such as health system and control measures become more important after the early spread. Our study should encourage further studies on MHCII alleles as potential risk factors in COVID-19 including assessment of local populations and specific allele distributions.
We obsn class="Gene">erved substantial differences in predicted Major Histocompatibility Complex II (MHCII) epitope presentation of SARS-CoV-2 proteins for different populations but only minor differences in predicted MHCI epitope presentation. A comparison of this predicted epitope MHC-coverage revealed for theearly phase of infection spread (till day 15 after reaching 128 observed infectioncases) highly significant negative correlations with thecase fatality rate. Specifically, this was observed in different populations for MHC class II presentation of the viral spike protein (p-value: 0.0733 for linear regression), theenvelope protein (p-value: 0.023), and the membrane protein (p-value: 0.00053), indicating that the high case fatality rates of COVID-19 observed in some countries seem to be related with poor MHC class II presentation and hence weak adaptive immune response against these viral envelope proteins. Our results highlight the general importance of theSARS-CoV-2 structural proteins in immunological control in early infection spread looking at a global census in various countries and taking case fatality rate into account. Other factors such as health system and control measures become more important after theearly spread. Our study should encourage further studies on MHCII alleles as potential risk factors in COVID-19 including assessment of local populations and specific allele distributions.
Authors: Venkata R Duvvuri; Bhargavi Duvvuri; Christilda Alice; Gillian E Wu; Jonathan B Gubbay; Jianhong Wu Journal: PLoS One Date: 2014-03-07 Impact factor: 3.240
Authors: Andrew D Davidson; Maia Kavanagh Williamson; Sebastian Lewis; Deborah Shoemark; Miles W Carroll; Kate J Heesom; Maria Zambon; Joanna Ellis; Philip A Lewis; Julian A Hiscox; David A Matthews Journal: Genome Med Date: 2020-07-28 Impact factor: 11.117
Authors: Shirley Sze; Daniel Pan; Clareece R Nevill; Laura J Gray; Christopher A Martin; Joshua Nazareth; Jatinder S Minhas; Pip Divall; Kamlesh Khunti; Keith R Abrams; Laura B Nellums; Manish Pareek Journal: EClinicalMedicine Date: 2020-11-12
Authors: Leonard Moise; Bethany M Biron; Christine M Boyle; Nese Kurt Yilmaz; Hyesun Jang; Celia Schiffer; Ted M Ross; William D Martin; Anne S De Groot Journal: Hum Vaccin Immunother Date: 2018-09-05 Impact factor: 3.452
Authors: Bethany Dearlove; Eric Lewitus; Hongjun Bai; Yifan Li; Daniel B Reeves; M Gordon Joyce; Paul T Scott; Mihret F Amare; Sandhya Vasan; Nelson L Michael; Kayvon Modjarrad; Morgane Rolland Journal: Proc Natl Acad Sci U S A Date: 2020-08-31 Impact factor: 12.779
Authors: Joshua M Francis; Del Leistritz-Edwards; Augustine Dunn; Christina Tarr; Jesse Lehman; Conor Dempsey; Andrew Hamel; Violeta Rayon; Gang Liu; Yuntong Wang; Marcos Wille; Melissa Durkin; Kane Hadley; Aswathy Sheena; Benjamin Roscoe; Mark Ng; Graham Rockwell; Margaret Manto; Elizabeth Gienger; Joshua Nickerson; Amir Moarefi; Michael Noble; Thomas Malia; Philip D Bardwell; William Gordon; Joanna Swain; Mojca Skoberne; Karsten Sauer; Tim Harris; Ananda W Goldrath; Alex K Shalek; Anthony J Coyle; Christophe Benoist; Daniel C Pregibon Journal: Sci Immunol Date: 2022-01-21